Cargando…
The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic Myelopathy
STUDY DESIGN: Case-control study. OBJECTIVES: Cervical spondylotic myelopathy (CSM) is the most common cause of spinal cord injury in adults aged over 55 years. However, since the onset is typically insidious, accurately diagnosing CSM can be challenging, often requiring referral to a subspecialist...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693067/ https://www.ncbi.nlm.nih.gov/pubmed/31448193 http://dx.doi.org/10.1177/2192568218815863 |
_version_ | 1783443640375312384 |
---|---|
author | Barkoh, Kaku Ohiorhenuan, Ifije E. Lee, Larry Lucas, Joshua Arakelyan, Anush Ornelas, Christopher Buser, Zorica Hsieh, Patrick Acosta, Frank Liu, John Wang, Jeffrey C. Hah, Raymond |
author_facet | Barkoh, Kaku Ohiorhenuan, Ifije E. Lee, Larry Lucas, Joshua Arakelyan, Anush Ornelas, Christopher Buser, Zorica Hsieh, Patrick Acosta, Frank Liu, John Wang, Jeffrey C. Hah, Raymond |
author_sort | Barkoh, Kaku |
collection | PubMed |
description | STUDY DESIGN: Case-control study. OBJECTIVES: Cervical spondylotic myelopathy (CSM) is the most common cause of spinal cord injury in adults aged over 55 years. However, since the onset is typically insidious, accurately diagnosing CSM can be challenging, often requiring referral to a subspecialist and advanced imaging. To help identify patients at risk for CSM, this case-control study compared responses to a series of 4 questions (DOWN questionnaire) in myelopathic and non-myelopathic patients. METHODS: Ninety-two patients, 46 with and 46 without myelopathy, were recruited for the study. Each patient answered 4 questions encompassing common symptoms associated with CSM. Responses between patient groups were compared, and Cohen’s κ was used to assess for agreement between responses and the diagnosis of myelopathy. RESULTS: We found a sensitivity of 91% and a κ of 0.54 to 3 positive responses and a sensitivity of 72% and a κ of 0.61 to 4 positive responses. CONCLUSIONS: Positive responses to 3 or more DOWN questions has high sensitivity and moderate agreement with the diagnosis of myelopathy based on history, physical exam, and review of advanced imaging by an orthopedic or neurological surgeon. The DOWN questionnaire is a potentially useful screening tool to identify patients at risk for CSM. |
format | Online Article Text |
id | pubmed-6693067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-66930672019-08-23 The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic Myelopathy Barkoh, Kaku Ohiorhenuan, Ifije E. Lee, Larry Lucas, Joshua Arakelyan, Anush Ornelas, Christopher Buser, Zorica Hsieh, Patrick Acosta, Frank Liu, John Wang, Jeffrey C. Hah, Raymond Global Spine J Original Articles STUDY DESIGN: Case-control study. OBJECTIVES: Cervical spondylotic myelopathy (CSM) is the most common cause of spinal cord injury in adults aged over 55 years. However, since the onset is typically insidious, accurately diagnosing CSM can be challenging, often requiring referral to a subspecialist and advanced imaging. To help identify patients at risk for CSM, this case-control study compared responses to a series of 4 questions (DOWN questionnaire) in myelopathic and non-myelopathic patients. METHODS: Ninety-two patients, 46 with and 46 without myelopathy, were recruited for the study. Each patient answered 4 questions encompassing common symptoms associated with CSM. Responses between patient groups were compared, and Cohen’s κ was used to assess for agreement between responses and the diagnosis of myelopathy. RESULTS: We found a sensitivity of 91% and a κ of 0.54 to 3 positive responses and a sensitivity of 72% and a κ of 0.61 to 4 positive responses. CONCLUSIONS: Positive responses to 3 or more DOWN questions has high sensitivity and moderate agreement with the diagnosis of myelopathy based on history, physical exam, and review of advanced imaging by an orthopedic or neurological surgeon. The DOWN questionnaire is a potentially useful screening tool to identify patients at risk for CSM. SAGE Publications 2018-12-04 2019-09 /pmc/articles/PMC6693067/ /pubmed/31448193 http://dx.doi.org/10.1177/2192568218815863 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (http://www.creativecommons.org/licenses/by-nc-nd/4.0/) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Articles Barkoh, Kaku Ohiorhenuan, Ifije E. Lee, Larry Lucas, Joshua Arakelyan, Anush Ornelas, Christopher Buser, Zorica Hsieh, Patrick Acosta, Frank Liu, John Wang, Jeffrey C. Hah, Raymond The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic Myelopathy |
title | The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic
Myelopathy |
title_full | The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic
Myelopathy |
title_fullStr | The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic
Myelopathy |
title_full_unstemmed | The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic
Myelopathy |
title_short | The DOWN Questionnaire: A Novel Screening Tool for Cervical Spondylotic
Myelopathy |
title_sort | down questionnaire: a novel screening tool for cervical spondylotic
myelopathy |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693067/ https://www.ncbi.nlm.nih.gov/pubmed/31448193 http://dx.doi.org/10.1177/2192568218815863 |
work_keys_str_mv | AT barkohkaku thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT ohiorhenuanifijee thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT leelarry thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT lucasjoshua thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT arakelyananush thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT ornelaschristopher thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT buserzorica thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT hsiehpatrick thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT acostafrank thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT liujohn thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT wangjeffreyc thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT hahraymond thedownquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT barkohkaku downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT ohiorhenuanifijee downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT leelarry downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT lucasjoshua downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT arakelyananush downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT ornelaschristopher downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT buserzorica downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT hsiehpatrick downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT acostafrank downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT liujohn downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT wangjeffreyc downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy AT hahraymond downquestionnaireanovelscreeningtoolforcervicalspondyloticmyelopathy |